Tag: T-DXd
DESTINY-Lung04 Delivers a First-Line PFS Advantage for Trastuzumab Deruxtecan in HER2-Mutant...
Results from a global Phase 3 trial demonstrated that trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) can delay disease progression longer than standard...
Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer:...
Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026
ESMO 2025: A New Generation of ADCs Shows Unprecedented Promise...
Compelling evidence presented at the European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025, in Berlin, Germany, has shown that a new generation of antibody-drug conjugates (ADCs) can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.
20-Hour Conjugation Bottlenecks – Confronting ADC Development Challenges with CDMOs
20-Hour Conjugation Bottlenecks – Confronting ADC Development Challenges with CDMOs
Trastuzumab Deruxtecan Demonstrates Clinical Activity in Neoadjuvant Setting in Patients with...
Patients diagnosed with hormone receptor-positive (HR+)/HER2-negative breast cancer frequently experience disease response to neoadjuvant therapy. However, following standard chemotherapy or endocrine therapy, even in combination with CDK4/6...
HER2-targeting Trastuzumab Deruxtecan Shows Promise in Patients with Non-breast/Gastric Cancers
Results from a phase I study investigating fam-trastuzumab deruxtecan-nxki (formerly known as DS-8201a; Enhertu®; Daiichi Sankyo and AstraZeneca) showed signs of clinical activity of...
